- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06509373
A Portal-based Advance Care Planning Intervention Among Community-Dwelling Persons Living With Cognitive Impairment (Portal-Voice)
August 27, 2026 updated by: Wake Forest University Health Sciences
The purpose of this research is to examine the feasibility of using a patient portal based advance care planning (ACP) tool to improve ACP discussions and documentation in persons living with cognitive impairment in outpatient primary care.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The goal of this study is to explore whether sending a portal-based ACP tool (called ACPVoice) paired with a motivational message within the patient portal before a routine primary care physician visit can improve ACP discussions and documentation within the electronic health record among persons living with cognitive impairment in outpatient primary care.
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 65 years old and older
- Diagnosis of recognized or probable mild cognitive impairment or mild dementia or elevated eRADAR score
- Completed visit with their primary care provider (PCP) within the past 12 months and have upcoming PCP visit in next 6 months
- Have an active patient portal account
Exclusion Criteria:
- Lives in a long-term care facility
- Severe vision impairment/blindness (as they need to be able to read portal messages)
- Enrolled in hospice
- Lacks decisional capacity as deemed by PCP
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
Community-dwelling persons living with cognitive impairment aged 65 and older with known or probable mild cognitive impairment or dementia or elevated eRADAR score (with decision-making capacity), who are affiliated with the Atrium-Wake Forest Baptist Health, have a primary care physician within the Atrium-Wake Forest Baptist Health Network, and have an active patient portal account.
|
Patients will have access to the standardized advance care planning questionnaires readily available already within their mychart account which is part of standard of care.
|
|
Experimental: ACPVoice Intervention
Community-dwelling persons living with cognitive impairment aged 65 and older with known or probable mild cognitive impairment or dementia or elevated eRADAR score (with decision-making capacity), who are affiliated with the Atrium-Wake Forest Baptist Health, have a primary care physician at one of the participating sites, and have an active patient portal account.
|
Eligible patients will be sent a secure MyChart message with a motivational message asking them to complete the advance care planning tool (ACPVoice) with their care partner/surrogate decision-maker or loved one before their upcoming primary care visit.
The ACPVoice tool will be attached electronically to the mychart message.
A reminder message will be sent to an non-responders with a different motivational message.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Engagement Rate
Time Frame: Up to month 6
|
Percentage of participants who open the advance care planning tool (ACPVoice) mychart message
|
Up to month 6
|
|
Percentage of Intervention Completion
Time Frame: Up to month 6
|
In the ACPVoice arm, completion was defined as completion of the ACPVoice questionnaire following outreach through the patient portal and follow-up reminders.
In the Standard of Care arm, completion was defined as completion of the standard Epic ACP questionnaire (ACP For My Care Team Questionnaire) available through the patient portal without additional prompting or outreach.
|
Up to month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Advance Care Planning Documentation Rates by Primary Care Providers
Time Frame: 12 months pre intervention, up to month 6 post intervention
|
Number of participants with documentation of advance care planning within the electronic health record by primary care provider.
Preintervention data collected from a chart review after participant enrolled in study.
|
12 months pre intervention, up to month 6 post intervention
|
|
Rate of Advance Care Planning Billing Code Usage
Time Frame: 12 months pre intervention, up to month 6 post intervention
|
Number of participants with advance care planning billing code usage (CPT codes 99497, 99498; HCPCS codes 1123, 1124).
Data collected from a chart review after participant enrolled in study.
|
12 months pre intervention, up to month 6 post intervention
|
|
Rate of Documented Designated Surrogate Decision Maker
Time Frame: 12 months pre intervention, month 6 post intervention
|
Number of participants with a documented designated surrogate decision maker in the electronic health record.
Data collected from a chart review after participant enrolled in study.
|
12 months pre intervention, month 6 post intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Advance Care Planning Documentation
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
High-quality advance care planning documentation will be defined as addressing ≥4 of the 8 core components with 1 point assigned for each of the following questions related to: health-related goals, what matters most/most important in their life, health-related worries/concerns, named surrogate decision-maker, how much information they would like to know, unacceptable states at the end-of-life, goals if their health was to worsen, and questions about advance care planning forms.
Score of 0-8 with 0 indicating no advance care planning questions answered to 8 indicating eight core advance care planning questions answered.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Telephone Advance Care Planning Completion Rates
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Defined as the number of patients who complete the advance care planning tool (ACPVoice) over the telephone.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Paper Advance Care Planning Documentation Rates
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Defined as the number of patients who were mailed and completed the advance care planning tool (ACPVoice) via mail.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Feeling Heard and Understood
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Data will be assessed via a RedCap survey with 4 questions: I felt heard and understood by this provider and team, I felt this provider and team put my best interests first when making recommendations about my care, I felt this provider and team saw me as a person, not just someone with a medical problem, I felt this provider and team understood what is important to me in my life.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Digital Health Literacy
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Data will be measured using the Brief Digital Health Care Literacy Scale.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Barrier to Adoption
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Data will be collected via qualitative interviews with participants and providers.
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Provider Survey Score
Time Frame: 6 months post implementation period
|
17 multiple choice items regarding provider opinion on the interventions acceptability, appropriateness, feasibility and overall satisfaction.
Total score range is 17-84 with a higher score indicating a more favorable opinion of the intervention.
|
6 months post implementation period
|
|
Participant Confidence Related to PCP Knowing What is Important to Them
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Data will be collected via a RedCap survey asking 5 questions: i.
How confident are you your primary care clinician/team knows what is important to you?, ii.
How confident are you that what is important to you will determine the medical care you receive in the future?
, iii.
To what extent did completing this care planning tool increase or decrease your sense of control over medical decisions?, iv.
Before completing the care planning tool, did your primary care clinician/team ask what is important to you? , and v.
After completing the care planning tool, did your primary care clinician/team ask what is important to you? .
|
6 months during the implementation period and up to 6 months post the implementation period
|
|
Preference-concordant Care
Time Frame: 6 months during the implementation period and up to 6 months post the implementation period
|
Data will be collected via Redcap survey asking "How strongly do you agree or disagree that your current medical/treatment plan meets your preferences".
|
6 months during the implementation period and up to 6 months post the implementation period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jennifer Gabbard, MD, Wake Forest University Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 19, 2024
Primary Completion (Actual)
June 27, 2025
Study Completion (Actual)
June 27, 2025
Study Registration Dates
First Submitted
July 12, 2024
First Submitted That Met QC Criteria
July 12, 2024
First Posted (Actual)
July 19, 2024
Study Record Updates
Last Update Posted (Actual)
August 31, 2026
Last Update Submitted That Met QC Criteria
August 27, 2026
Last Verified
December 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Dementia
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Patient Care Management
- Patient Care Planning
- Comprehensive Health Care
- Standard of Care
- Advance Care Planning
Other Study ID Numbers
- IRB00112143
- 5K23AG070234-03 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.